NOTE: This video is ONLY available to watch in selected countries and geographies
Tobias Steinke (Düsseldorf, Germany), Matteo Tozzi (Varese, Italy) and Robert Shahverdyan (Hamburg, Germany) give their reactions to the publication in the New England Journal of Medicine of the IN.PACT AV Access clinical trial data, focusing on some of the key data as well as delving into how it has changed their practice and what impact the findings might have in terms of the quality of life for their patients.
Steinke says he was “really impressed” by the results since “this is the only and first trial that met both safety and effectiveness end points”. He also states that the finding that the use of a drug-coated balloon (DCB) is “superior” to plain balloon angioplasty “really helps us for therapy decisions in our daily practice”, concluding that “we now have scientific proof to justify the use of the DCB.”
Tozzi highlights some of the key data points including the primary patency of the target lesion which was 24.5% higher in the DCB group (72.5%) than the PTA group (48.0%). He further adds that a big advantage with the use of DCBs is the lower number of reinterventions needed, concluding that there is “strong and incontrovertible evidence” that the “DCB must be the gold standard in the treatment of vascular access stenosis”.
Shahverdyan explains that the publication of the IN.PACT AV Access results in the NEJM “changed the way I decide to use balloon angioplasty”. He notes that this data now confirms “that you can and should use a DCB” in the first instance. Shahverdyan also suggests that patients will have “better quality of life” due to the reduction in hospitalisation.
This video is sponsored by Medtronic.